Je was op zoek naar: cholangitis (Deens - Engels)

exkretorisk cholangitis
excretory cholangitis

akut obstruktiv cholangitis
acute obstructive cholangitis

gulsot cholecystitis cholangitis
cholecystitis cholangitis

leverinsuffi- ciens, cholangitis, fedtlever
hepatic failure, cholangitis, fatty liver

stigning i bilirubin og gulsot cholecystitis cholangitis
gastro oesophageal reflux disease pancreatitis gastritis gastrointestinal perforations* increase in bilirubin and jaundice cholecystitis cholangitis

leverfunktion, cholestase og gulsot, skade på cholangitis
hepatic enzymes and function abnormalities, cholestasis and jaundice, hepatocellular damage and hepatitis, cholangitis

dilatation kan dog være svær at se ved tidlig obstruktion og skleroserende cholangitis.
but dilatation maybe subtle in early obstruction and sclerosingcholangitis.

unormal leverenzymtal og funktion, cholestase og gulsot, skade på leverceller og hepatitis, cholangitis
and function abnormalities, cholestasis and

gulsot, komplikationer af cholelithiasis (f.eks. cholecystitis, cholangitis, galdevejskolik osv.)
jaundice, complications of cholelithiasis (e.g cholecystitis, cholangitis, biliary colic, etc).

unormale leverenzymtal og leverfunktion, cholestase og gulsot, skade på leverceller og hepatitis, cholangitis trombose i leverarterie, venokklusiv leversygdom leversvigt, galdevejsstenose
hepatic enzymes and function abnormalities, cholestasis and jaundice, hepatocellular damage and hepatitis, cholangitis hepatitic artery thrombosis, venoocclusive liver disease hepatic failure, bile duct stenosis

alle patienter med colitis ulcerosa, som har forhøjet risiko for dysplasi eller colon cancer (for eksempel patienter med langvarig colitis ulcerosa eller primær sklerotisk cholangitis), eller som tidligere har haft dysplasi eller colon cancer, bør screenes for dysplasi med reglmæssige intervaller før behandling og under deres sygdomsforløb.
all patients with ulcerative colitis who are at increased risk for dysplasia or colon carcinoma (for example, patients with long-standing ulcerative colitis or primary sclerosing cholangitis), or who had a prior history of dysplasia or colon carcinoma should be screened for dysplasia at regular intervals before therapy and throughout their disease course.